Form 8-K - Current report:
SEC Accession No. 0001326190-24-000046
Filing Date
2024-11-12
Accepted
2024-11-12 06:46:29
Documents
17
Period of Report
2024-11-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20241111x8k.htm   iXBRL 8-K 53026
2 EX-10.1 alt-20241111xex10d1.htm EX-10.1 88846
3 EX-99.1 alt-20241111xex99d1.htm EX-99.1 21555
4 GRAPHIC alt-20241111xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-24-000046.txt   343945

Data Files

Seq Description Document Type Size
5 EX-101.SCH alt-20241111.xsd EX-101.SCH 3272
6 EX-101.LAB alt-20241111_lab.xml EX-101.LAB 18717
7 EX-101.PRE alt-20241111_pre.xml EX-101.PRE 12850
19 EXTRACTED XBRL INSTANCE DOCUMENT alt-20241111x8k_htm.xml XML 4916
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 241443114
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)